MX2014004132A - Señuelos humanos notch1. - Google Patents

Señuelos humanos notch1.

Info

Publication number
MX2014004132A
MX2014004132A MX2014004132A MX2014004132A MX2014004132A MX 2014004132 A MX2014004132 A MX 2014004132A MX 2014004132 A MX2014004132 A MX 2014004132A MX 2014004132 A MX2014004132 A MX 2014004132A MX 2014004132 A MX2014004132 A MX 2014004132A
Authority
MX
Mexico
Prior art keywords
amino acid
egf
repeat
fusion proteins
sequence
Prior art date
Application number
MX2014004132A
Other languages
English (en)
Inventor
Jan Kitajewski
Carrie Shawber
Thaned Kangsamaksin
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48044136&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014004132(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Columbia filed Critical Univ Columbia
Publication of MX2014004132A publication Critical patent/MX2014004132A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan en la presente proteínas de fusión Notch1. Estas proteínas de fusión comprenden aminoácidos consecutivos la secuencia de la cual, que comienza en el N-terminal de la proteína de fusión, es idéntica a la secuencia de los aminoácidos en un dominio extracelular de una proteína de receptor Notch1 humano y una porción Fc de un anticuerpo. La secuencia de aminoácidos del dominio extracelular (ECD) de la proteína humana del receptor Notch1 comienza con el aminoácido presente en el N-terminal de repetición tipo EGF 10 y se extiende al menos a través del aminoácido en el C-terminal de repetición tipo EGF 23. La porción en el N-terminal de la ECD de la proteína humana del receptor Notch1 se puede extender hasta el aminoácido en el C-terminal de repetición tipo EGF 24 o se puede extender hasta el aminoácido en el C-terminal de repetición tipo EGF 36. Se proporcionan también composiciones de estas proteínas de fusión. También se proporcionan métodos de tratamiento de degeneración macular relacionada con la edad (AMD), retinopatía diabética y cáncer usando las proteínas de fusión aquí descritas.
MX2014004132A 2011-10-04 2012-10-04 Señuelos humanos notch1. MX2014004132A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161543186P 2011-10-04 2011-10-04
PCT/US2012/058662 WO2013052607A1 (en) 2011-10-04 2012-10-04 Human notch1 decoys

Publications (1)

Publication Number Publication Date
MX2014004132A true MX2014004132A (es) 2014-07-24

Family

ID=48044136

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014004132A MX2014004132A (es) 2011-10-04 2012-10-04 Señuelos humanos notch1.

Country Status (19)

Country Link
US (2) US9738708B2 (es)
EP (1) EP2763700A4 (es)
JP (1) JP2014532061A (es)
KR (1) KR20140093942A (es)
CN (1) CN103917247A (es)
AR (1) AR088048A1 (es)
AU (1) AU2012318664A1 (es)
BR (1) BR112014008025A2 (es)
CA (1) CA2850944A1 (es)
CL (1) CL2014000852A1 (es)
HK (1) HK1198427A1 (es)
IL (1) IL231920A0 (es)
MX (1) MX2014004132A (es)
PE (1) PE20141479A1 (es)
RU (1) RU2014117160A (es)
SG (1) SG11201401186RA (es)
TW (1) TW201329105A (es)
WO (1) WO2013052607A1 (es)
ZA (1) ZA201403044B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005111072A2 (en) 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Notch-based fusion proteins and uses thereof
NZ618129A (en) 2007-08-23 2015-05-29 Univ Columbia Compositions of humanized notch fusion proteins and methods of treatment
ES2532405T3 (es) 2008-08-22 2015-03-26 The Trustees Of Columbia University In The City Of New York Proteínas de fusión basadas en Notch3 humanas como inhibidores señuelo de la señalización de Notch3
AR088048A1 (es) * 2011-10-04 2014-05-07 Univ Columbia Señuelos notch1 humanos
CN105585636B (zh) * 2015-11-24 2020-03-03 南方医科大学 一种人NOTCH1 NICD蛋白Ser2162位点磷酸化抗体及其制备方法和应用
WO2017205651A1 (en) * 2016-05-25 2017-11-30 The Trustees Of Columbia University In The City Of New York Human notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and dll-notch signaling
WO2023192802A1 (en) * 2022-04-01 2023-10-05 The Board Of Trustees Of The University Of Illinois Notch1 and notch4 decoys and methods of use

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
IE20030749A1 (en) 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta binding domains in torporythmic proteins, and methods based thereon
US6716974B1 (en) 1996-05-31 2004-04-06 Maine Medical Center Research Institute Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
FR2751986B1 (fr) 1996-08-01 1998-12-31 Inst Nat Sante Rech Med Gene implique dans le cadasil, methode de diagnostic et application therapeutique
US6379925B1 (en) 1997-06-18 2002-04-30 The Trustees Of Columbia University In The City Of New York Angiogenic modulation by notch signal transduction
US6703221B1 (en) 1999-08-19 2004-03-09 Chiron Corporation Notch receptor ligands and uses thereof
GB9927328D0 (en) 1999-11-18 2000-01-12 Lorantis Ltd Immunotherapy
US6689744B2 (en) 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses
EP1448599A2 (en) 2001-11-14 2004-08-25 Lorantis Limited Inhibitors of the notch signalling pathway for use in the treatment of cancer
JP2006506322A (ja) 2002-04-05 2006-02-23 ロランティス リミテッド 内科療法
JP2006513260A (ja) 2002-08-03 2006-04-20 ロランティス リミテッド Ｎｏｔｃｈシグナル伝達経路調節因子の複合体およびその薬物治療への使用
AU2003267563A1 (en) 2002-09-10 2004-04-30 Lorantis Limited Pharmaceutical composition and medical treatments comprising notch ligand proteins
WO2005111072A2 (en) 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Notch-based fusion proteins and uses thereof
US20060134121A1 (en) 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
WO2006047878A1 (en) 2004-11-03 2006-05-11 British Columbia Cancer Agency Branch Cancer therapeutics and methods for their use
KR20080025761A (ko) 2005-07-29 2008-03-21 더 제너럴 하스피탈 코포레이션 피부 손상을 감소시키는 방법 및 조성물
JP5478254B2 (ja) 2006-10-19 2014-04-23 ジェネンテック， インコーポレイテッド 抗ノッチ３アゴニスト抗体とノッチ３関連疾患の治療におけるその使用
EP2125887A4 (en) * 2007-01-24 2010-11-10 Oncomed Pharm Inc COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF CANCER
NZ618129A (en) * 2007-08-23 2015-05-29 Univ Columbia Compositions of humanized notch fusion proteins and methods of treatment
SI2307051T1 (sl) * 2008-07-08 2015-04-30 Oncomed Pharmaceuticals, Inc. Notch-vezavna sredstva in antagonisti ter postopki njihove uporabe
ES2532405T3 (es) 2008-08-22 2015-03-26 The Trustees Of Columbia University In The City Of New York Proteínas de fusión basadas en Notch3 humanas como inhibidores señuelo de la señalización de Notch3
AR088048A1 (es) * 2011-10-04 2014-05-07 Univ Columbia Señuelos notch1 humanos

Also Published As

Publication number Publication date
IL231920A0 (en) 2014-05-28
TW201329105A (zh) 2013-07-16
SG11201401186RA (en) 2014-04-28
US20170306006A1 (en) 2017-10-26
AU2012318664A1 (en) 2014-05-22
AR088048A1 (es) 2014-05-07
EP2763700A1 (en) 2014-08-13
ZA201403044B (en) 2016-01-27
EP2763700A4 (en) 2015-05-27
US9738708B2 (en) 2017-08-22
US10227399B2 (en) 2019-03-12
JP2014532061A (ja) 2014-12-04
KR20140093942A (ko) 2014-07-29
HK1198427A1 (en) 2015-04-24
RU2014117160A (ru) 2015-11-10
WO2013052607A1 (en) 2013-04-11
WO2013052607A9 (en) 2014-04-10
PE20141479A1 (es) 2014-11-05
US20140271643A1 (en) 2014-09-18
CA2850944A1 (en) 2013-04-11
CN103917247A (zh) 2014-07-09
CL2014000852A1 (es) 2014-12-12
BR112014008025A2 (pt) 2017-04-11

Similar Documents

Publication Publication Date Title
MX2014004132A (es) Señuelos humanos notch1.
PH12019500644A1 (en) Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
MX2021006017A (es) Polipeptidos de folistatina y sus usos.
PE20170142A1 (es) Proteina de fusion que inhibe angiogenesis o crecimiento y uso de la misma
PE20190743A1 (es) Metodos para el tratamiento de la atrofia muscular y enfermedad osea con el uso de proteinas trap hibridas novedosas del ligando actriib
EA201290722A1 (ru) Рекомбинантный белок эксендина-4 и его аналога, способ их приготовления и применение
AU2015269210A8 (en) Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
CU20120116A7 (es) Polipéptidos que se enlazan a dr5 humana con efectos agonistas, que comprenden uno o más monómeros de un único dominio variable, utiles en el tratamiento de enfermedades y trastornos asociados con dr5
MX2021006856A (es) Uso de un peptido para modular la homeostasis de los acidos biliares o tratamiento de una enfermedad relacionada con los acidos biliares.
MX2012007318A (es) Proteina de fusion de la region constante del anticuerpo-cd47 tetravalente para usarse en terapia.
EA201201047A1 (ru) Способы и композиции, в которых применяют слитые полипептиды fgf 23
UA107330C2 (uk) Туберкульозний білок rv3616c та його застосування
NO20071093L (no) Nye anti-IGF-IR-antistoffer og anvendelse derav
EA201291138A1 (ru) Способы, композиции и наборы для лечения нарушений, связанных с минерализацией матрикса
EA201490393A1 (ru) Соматотропный гормон пролонгированного действия и способы его получения
MY162564A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
NZ621868A (en) Growth hormone polypeptides and methods of making and using same
NZ603570A (en) Biological materials related to her3
PE20141727A1 (es) Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas
AR079114A1 (es) Proteinas de enlace de antigenos anti-orai1 y usos de las mismas
BRPI1015424A2 (pt) métodos e composições utilizando peptídeos e proteínas com elementos de terminação c.
MX2010008206A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf.
PE20141561A1 (es) Anticuerpos anti-lrp5 y metodos de uso
UA107180C2 (uk) Туберкульозний білок rv1753c, композиція, що його містить, та застосування
AU2018249796A1 (en) Antibody Fc variants for improving blood half-life